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ABSTRACT 
 
Lindsey M. Carpenter: Toolkit to Improve Provider Adherence to Metabolic Monitoring of 
Atypical Antipsychotics for Youths  
(Under the direction of Grace Hubbard) 
 
Problem: The use of atypical antipsychotic medications (AAPs) to treat bipolar and other 
mood disorders has increased in pediatric populations.  The potential metabolic side effects of 
these medications increase the risk of negative health outcomes.  Providers are aware of practice 
guidelines regarding these medications but fail to adhere to them.  Practice toolkits are quality-
improvement interventions aimed at improving guideline compliance. 
Purpose: The purpose of this project was to implement a toolkit to increase adherence to 
guidelines for metabolic measures in patients aged 5-18 with a bipolar disorder taking an atypical 
antipsychotic.   
Methods: A toolkit containing necessary order, assessment, and documentation forms 
was deployed in an outpatient mental health office in North Carolina. Plan-Do-Study-Act cycles 
were conducted to guide implementation. Providers included a Doctor of Osteopathic Medicine, 
Psychiatric-Mental Health Nurse Practitioners, and a Physician Assistant. Chart audits were 
conducted and compliance data was displayed as run charts compared to baseline data. Outcome 
measures included: completion of metabolic assessment, appropriate laboratory ordering, and 
completion of vital sign measurements. 
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Results: Outcome measures showed improved adherence rates to monitoring vital signs, 
ordering appropriate labs, and performing a metabolic assessment.  These improvements varied 
among providers.  
Implications: While improvements occurred, there were still barriers to implementation 
such as lack of time.  Ongoing assessment of barriers is necessary to sustain the changes and to 
ensure consistent application of the guideline recommendations by all providers.   
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CHAPTER 1: PROBLEM  
The diagnosis of bipolar spectrum disorders, Disruptive Mood Dysregulation Disorder 
(DMDD), and use of atypical antipsychotic medications (AAPs) or second-generation 
antipsychotics (SGAs) to treat these disorders have increased in the pediatric population in recent 
years. A common and potentially serious side effect of these medications is a condition called 
metabolic syndrome (De Hert, Dobbelaere, Sheridan, Cohen, & Correll, 2011; Haddad & 
Sharma, 2007; Koch & Scott, 2012; G. M. Reeves et al., 2013; Walter et al., 2008).  To combat 
this growing epidemic of iatrogenic side effects, resources and treatment suggestions have been 
developed for providers who treat this population.   
Professional organizations have developed practice guidelines that promote evidence-
based practice to deliver the best care for these patients, however, these guidelines are severely 
underused in practice.  The guideline formulated by a collaboration of the American Diabetes 
Association (ADA), the American Psychiatric Association (APA), the American Association of 
Clinical Endocrinologists (AACE), and the North American Association for the Study of 
Obesity (NAASO) (2004) provides recommendations for the monitoring of metabolic 
parameters for patients started on AAPs (Appendix A).  Guidelines developed by the American 
Academy of Child and Adolescent Psychiatry (AACAP) outline the assessment and treatment of 
children and adolescents with a bipolar disorder and those treated with AAPs (Findling et al., 
2011; McClellan, et al., 2007).  These guidelines have been widely distributed electronically and 
in print, presented in symposiums across the nation, cited in quality improvement studies, and 
are readily available for access by providers (Velligan et al., 2013).  While the rates of 
  
 
 
2 
compliance with these practice guidelines vary widely, the general consensus supports that these 
evidence-based recommendations are often not utilized in clinical practice as evidenced in 
studies of managed care and commercial insurance databases (Koch & Scott, 2012; Velligan et 
al., 2013).  The findings of several studies reveal that most providers are familiar with these 
guidelines; however, awareness of these guidelines does not translate into performance of the 
recommended assessment, treatment, and monitoring (Jeffrey, 2015; Khan, Shaikh, & Ablah, 
2010; Laugharne, Waterreus, Castle, & Dragovic, 2016; Sugawara et al., 2014; Walter et al., 
2008; Wiechers et al., 2012).  Researchers have also found that providers may be compliant with 
some of the recommendations, but not all of them, or do not adhere to the recommended 
schedule for monitoring (Khan et al., 2010; Walter et al., 2008).  Suppes, McElroy, and 
Hirschfield (2007) found that providers believe metabolic syndrome is a significant health risk 
that requires monitoring and treatment yet, few diagnosed it in their patients and even fewer 
could identify the correct components for diagnosis of metabolic syndrome, even though they 
had diagnosed it in their patients.  The findings of these studies support the pervasiveness of this 
gap in evidence-based care delivery using AAPs that can have serious physical and psychiatric 
implications.  
Mental health providers at an outpatient mental health practice in Western North Carolina 
prescribes AAPs for children and adolescents without the benefit of consistent use of practice 
guidelines.  This practice treats approximately fifty children ages 5-18 per year who are 
diagnosed with bipolar spectrum disorders or DMDD. 
The purpose of this Doctor of Nursing Practice (DNP) project was to synthesize 
evidence-based guidelines and develop and implement a toolkit customized for this practice.  
Providers in this office implemented the toolkit to treat children and adolescents ages 5-18 years 
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diagnosed with a bipolar spectrum disorder or DMDD who are treated with an AAP. Emphasis 
was given to guideline recommendations for the prevention of weight gain and monitoring of 
metabolic side effects.  The DMDD diagnosis was included in the project because of the 
possibility of the use of AAPs in the treatment of symptoms.  Expected outcomes in respect to 
use of the toolkit were increased rates of provider compliance with guideline recommendations 
for metabolic assessment. Other outcome measures included were: completion of metabolic 
assessment, completion/recording of vital sign measurements, and appropriate laboratory 
ordering based on guidelines recommendations.   
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CHAPTER 2: LITERATURE SEARCH PROCESS 
Searches for relevant articles were conducted across three electronic databases, CINAHL, 
PsychInfo, and PubMed. (Appendix B).  The sampling frame of the study included research 
articles that focused on AAP use, the metabolic side effects of AAPs in children and adolescents, 
toolkit use in quality improvement, evidence-based guidelines, and barriers to the use of practice 
guidelines.  Inclusion criteria included full-text articles published in English between 2007-2017.  
The keyword searches included two or more of the following terms: bipolar disorders, 
atypical antipsychotics, metabolic side effects, weight gain, practice guideline, children, and 
adolescents. The abstracts of the articles were reviewed and articles were included if they met the 
inclusion criteria.  Duplicate publications of key articles were eliminated.  A manual search of 
the reference lists of key studies and articles was also performed. After a detailed review of the 
articles, 40 articles met the inclusion criteria of the study. 
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CHAPTER 3: REVIEW OF LITERATURE 
Bipolar Spectrum Disorder Diagnosis in Children and Adolescents 
 
Due to increased awareness, assessment, and treatment options, there has been a surge in 
the diagnosis of bipolar spectrum disorders (BSD) in younger patients in the United States 
(Birmaher, 2013; Crowley et al., 2014).  The diagnosis of bipolar disorders in youth in the 
outpatient setting has increased 40-fold in the past 10 years and inpatient hospitalizations for 
these patients have increased 4-fold (Singh, Ketter, & Chang, 2010). Specifically, approximately 
2.7% of persons 12-21 years old have a bipolar disorder with the percentage increasing to 5-
6.7% when including those with subsyndromal manic symptoms (Birmaher, 2013; Crowley et 
al., 2014).  
The introduction of the fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) by the American Psychiatric Association (APA) in 2013 introduced 
significant changes to bipolar spectrum and depressive disorder diagnoses including the addition 
of the Disruptive Mood Dysregulation Disorder (DMDD) diagnosis for children and adolescents. 
The DMDD diagnosis was created in response to concerns about the potential over-diagnosis of 
bipolar disorders in the pediatric population (APA, 2013). This diagnosis can be used in children 
ages 6 to 18 years who exhibit “Persistent irritability and frequent episodes of extreme behavior 
dyscontrol (APA, 2013, p. 156).”  The age of onset of DMDD symptoms should be before age 
10 years.  APA (2013, p. 156) diagnostic criteria include:  
- Severe, recurrent verbal and/or behavioral outbursts that are out of proportion in 
intensity and duration to the trigger 
  
 
 
6 
- The outbursts are inconsistent with developmental level and occur an average of three 
or more times a week 
- The mood between outbursts is persistently irritable or angry, most of the day, nearly 
every day, and is observable 
- The symptoms are present for 12 or more months in at least two settings and 
symptoms are not absent for more than three consecutive months 
- Symptoms should not be better explained by another disorder, substance abuse, 
medical, or neurological condition 
- The person has never experienced a hypomanic or manic episode and the symptoms 
occur at other times besides a major depressive episode 
- It cannot coexist with Oppositional Defiant Disorder, Intermittent Explosive 
Disorder, or a bipolar disorder.   
In the DSM-5 (2013), bipolar and related disorders include: Bipolar I Disorder, Bipolar II 
Disorder, Cyclothymic Disorder, Substance/Medication-Induced Bipolar and Related Disorders, 
Bipolar and Related Disorders Due to Another Medical Condition, Other Specified Bipolar and 
Related Disorders, and Unspecified Bipolar and Related Disorders.  These disorders are based on 
diagnostic criteria using three episodes of symptoms – major depressive, hypomanic, and manic.  
Differences among the disorders are based on the presence of certain episodes, severity, length of 
the episode, and cause.   
The diagnostic criteria for a major depressive episode includes five or more of the 
following symptoms that are a change from normal functioning for at least two weeks: depressed 
mood (or irritable mood in children and adolescents) or diminished interest or loss of pleasure 
for most of the day, nearly every day, and changes to appetite/weight, changes to sleep, 
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psychomotor retardation/agitation, fatigue, feelings of worthlessness or extreme guilt, problems 
with concentration or decision-making, or suicidal thoughts or actions (APA, 2013).  A 
hypomanic episode is a period of abnormally and persistently elevated, expansive, or irritable 
mood and increased activity or energy, lasting at least four consecutive days for most of the day, 
nearly every day (APA, 2013).  Three or more (four if the mood is irritable) of the symptoms that 
must be present in hypomania include: inflated self-esteem or grandiosity, decreased need for 
sleep, more talkative, flight of ideas or racing thoughts, distractibility, increase in goal-directed 
activity, and/or excessive involvement in risky behaviors.  A manic episode is similar to a 
hypomanic episode in criteria but the symptoms are more severe and lasts for at least a week (or 
less if hospitalization is necessary due to the severity of symptoms) (APA, 2013).   
To meet diagnostic criteria for bipolar I disorder, a manic episode is required where as a 
major depressive or hypomanic episode is not required.  For bipolar II disorder, the person must 
have experienced at least one hypomanic and at least one major depressive episode, but cannot 
have experienced a manic episode.  In cyclothymic disorder, hypomanic and depressive 
symptoms that do not meet criteria for full episodes must be present for at least two years for 
adults and one year for children and adolescents with persistent symptoms for more than two 
months at a time.  For the diagnosis of substance/medication-induced bipolar and related 
disorders, mood disturbances (elevation or depression) must occur during or soon after substance 
intoxication, withdrawal, or medication exposure.  The diagnosis of bipolar and related Disorders 
due to another medical condition is specified when it is caused by a known medical condition 
evident in history, physical examination, or lab findings.  The diagnosis of Specified Bipolar and 
Related Disorders refers to episodes that do not meet criteria for the number of symptoms for an 
episode or length of episode, a hypomanic episode without a prior major depressive episode, and 
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short-duration cyclothymia.  Unspecified Bipolar and Related Disorders is diagnosed when 
symptoms that are characteristic of a bipolar disorder that cause significant distress or 
impairment that do not meet full criteria for any other bipolar and related disorder.  As with 
DMDD, symptoms of these disorders cannot be explained by another psychiatric disorder, 
substance abuse, medical or neurological condition (unless otherwise specified) (APA, 2013). 
According to the APA (2013), children and adolescents with a BSD are more likely to 
have increased familial rates of a BSD.  Onset of symptoms during childhood or adolescence 
may be associated with a more severe lifetime course of the illness.  In Cyclothymic Disorder, 
the mean age of onset is 6.5 years of age for children (APA, 2013). 
Treatment Using Atypical Antipsychotic Medication 
 
 Options are limited for the treatment of bipolar disorders in children and adolescents. 
Currently, the only AAP medications that are approved by the Food and Drug Administration 
(FDA) for the treatment of Bipolar I Disorder Mixed/Manic in children and adolescents are: 
aripiprazole (Abilify) (ages 10-17), risperidone (Risperdal) (ages 10-17), olanzapine (Zyprexa) 
(ages 13-17), quetiapine (Seroquel) (ages 10-17), and lithium (ages 12+) (Stahl, 2014).  
Olanzapine in combination with fluoxetine (Symbyax) is approved for ages 10-17 years for the 
treatment of the depressive phase of Bipolar I disorder (Stahl, 2014).  Off label use of AAPs is 
common practice by providers due to the limited numbers of medications with FDA approval for 
the symptoms of concern.  This includes cases of subsymdromal symptoms, when a specific 
diagnosis cannot be made, or in cases where another bipolar spectrum disorder besides Bipolar I 
Disorder is suspected (Olfson, Blanco, Liu, Wang, & Correll, 2012).  As the number of AAP 
medications and indications approved by the FDA increases, the use of AAPs is expected to 
increase (Olfson et al., 2012).   
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Another factor contributing to their use is that randomized controlled trials (RCTs) have 
been conducted in this age group and show they are superior to valproic acid and lithium in 
treating mania in this population (Crowley et al., 2014).  RCTs on newer AAPs that have shown 
efficacy in adults are now being conducted in the pediatric population.  AAPs also have a lower 
propensity for causing bothersome, acute and chronic extrapyramidal side effects than typical 
antipsychotics (Olfson et al., 2012).  Other efforts have encouraged the use of AAPs including: 
greater acceptance of mental illness and treatment in general, greater public acceptance of 
psychiatric medications, and marketing by pharmaceutical companies (Olfson et al., 2012).  
Their use remains controversial due to the lack of population-specific data, ongoing debate about 
the prevalence of bipolar illness in children and adolescents, and the potential side effects 
(Crowley et al., 2014).  
Metabolic Side Effects of Atypical Antipsychotic Medications 
 
Atypical antipsychotics (AAPs) are widely used due to their overall efficacy and 
tolerability, especially when compared to their older counterparts.  However, AAPs have a 
unique side effect profile.  Due to their strong binding affinity to the 5-HT2 serotonin receptor, 
they can cause metabolic side effects generally not seen in their predecessors (Ronsley, 
Raghuram, Davidson, & Panagiotopoulos, 2011).  The metabolic side effects of AAPs include, 
but are not limited to: weight gain, increased blood sugar levels, increased triglycerides, and 
increased cholesterol (De Hert, Dobbelaere, Sheridan, Cohen, & Correll, 2011; Haddad & 
Sharma, 2007; Koch & Scott, 2012; G. M. Reeves et al., 2013; Walter et al., 2008).  The side 
effects of increased appetite and sedation can increase caloric intake and decrease resting 
metabolic rate (Harvard Medical School, 2009).  These metabolic side effects place patients at 
increased risk for long-term health implications including: obesity, insulin resistance, 
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dyslipidemia, hypertension, diabetes mellitus, stroke, coronary heart disease, and earlier 
mortality (Koch & Scott, 2012; G. M. Reeves et al., 2013; Walter et al., 2008).  Weight gain is 
growing as one of the most troubling side effects and is a significant factor in treatment 
adherence (Kumra et al., 2008; R. Reeves, Kaldany, Lieberman, & Vyas, 2009).  This iatrogenic 
weight gain can be rapid, profound and may not plateau even after one year on the medication 
(Kumra et al., 2008).  Children and adolescents in the hospital setting who are receiving AAPs 
are three times more likely to be overweight than unaffected peers (Martinez-Ortega et al., 
2013).  Adolescents may be more vulnerable to metabolic side effects and are more likely to 
experience cardiovascular and metabolic disturbances as adults (De Hert, Dobbelaere, Sheridan, 
et al., 2011; Harvard Medical School, 2009; Jeffrey, 2015). 
These metabolic side effects not only lead to physical comorbidities, but also 
psychosocial comorbidities. These sides effects decrease quality of life, proliferate the stigma 
associated with mental illness, exacerbate depression and anxiety, negatively influence self-
esteem and body image, impact the therapeutic relationship with the prescriber, and lead to 
decreased treatment adherence despite symptom improvement (Haddad & Sharma, 2007; 
Harvard Medical School, 2009).  Obesity increases the likelihood that the young person will 
experience bullying, discrimination, achieve lesser educational and employment goals, and have 
lower incomes as adults (The Joanna Briggs Institute, 2007).  The failure to adhere to treatment 
with AAPs can result in destabilization of psychiatric symptoms and related sequelae of 
symptom reemergence including mood and behavioral instability, recurrence of suicidal 
thoughts, and/or psychosis (R. Reeves et al., 2009).   
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Monitoring of Metabolic Side Effects  
 
The presence of potential metabolic side effects is still severely under-recognized by 
providers, despite the seriousness of the consequences (Velligan et al., 2013).  Patients who 
suffer from mental illness are less likely to receive the appropriate health screenings in the 
primary care setting (Velligan et al., 2013).  Furthermore, mental health providers may be the 
only healthcare provider the patient uses for care of any kind (Sernyak, 2007; Suppes, McElroy, 
& Hirschfeld, 2007; Velligan et al., 2013).  These facts further underline the importance of 
adherence to metabolic monitoring recommendations by psychiatric healthcare providers.  
Monitoring of metabolic side effects for patients on AAPs includes: assessment of height, 
weight, body-mass index (BMI), waist circumference, blood sugar, and cholesterol values.  It is 
of particularly important to monitor these symptoms from day one of treatment as the side effects 
can be dramatic and may occur early, especially the onset of weight gain (R. Reeves et al., 2009).  
Failure to monitor for these side effects can lead to increased mortality caused by diabetic 
ketoacidosis and cardiovascular disease (Owen et al., 2013).  Patients diagnosed with a bipolar 
spectrum disorder or schizophrenia are more likely to die of cardiovascular disease than of 
suicide (R. Reeves et al., 2009).   
Recommendations for Management of Metabolic Side Effects  
 
 Numerous studies have been conducted to determine the most effective ways to handle 
metabolic side effects that may occur with AAP treatment.  Both pharmacological and 
nonpharmacological interventions may be used to manage AAP metabolic side effects, such as, 
changing to a different AAP with a lower metabolic risk, adding medications such as metformin, 
topiramate, orlistat, amantadine, or sibutramine, and/or adding a diet and exercise plan (Kumra et 
al., 2008; G. M. Reeves et al., 2013).  Most of the research to date has been conducted with 
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adults, thus, the efficacy of these approaches for managing AAP side effects in children is 
limited. (G. M. Reeves et al., 2013).  Further, the addition of another medication to the regimen 
to decrease appetite or to promote weight loss also introduces the risk of destabilizing the child’s 
psychiatric symptoms and introduces the possibility of even more side effects that will need to be 
managed (Kumra et al., 2008).  
Early intervention to mitigate potential side effects is imperative as pediatric patients who 
have never taken atypical antipsychotic medications in the past are more prone to gain weight 
rapidly (Correll, Sheridan, & DelBello, 2010; De Hert, Dobbelaere, Sheridan, Cohen, & Correll, 
2011).  Early intervention programs to prevent weight gain that combine diet, physical activity, 
and behavioral therapy are shown to be more effective, but do decline in efficacy over time (The 
Joanna Briggs Institute, 2007; Lowe & Lubos, 2008).  Evidence-based behavioral interventions 
that focus on diet and activity level have been developed for obese children without a mental 
health disorder, but these have not been tested in children and adolescents taking AAPs (Kumra 
et al., 2007).  Psychoeducational interventions alone to do not seem to impact weight loss (Lowe 
& Lubos, 2008).   
The Stoplight or Traffic Light diet that reduces total energy consumption while teaching 
smarter food choices has been shown to be successful with improving healthy eating habits in 
families with children and adolescents (The Joanna Briggs Institute, 2007).  Specific 
interventions, such as providing examples of healthy meals and providing guidance like choosing 
low-fat or skim milk over whole fat, are more effective than general advice to reduce fat intake 
in the general population (The Joanna Briggs Institute, 2007). Also, more frequent visits where 
diet, exercise, and sedentary behaviors are discussed can increase weight loss success (The 
Joanna Briggs Institute, 2007).  One study with adolescents in a group-home setting successfully 
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demonstrated weight loss and increased physical activity by implementation of the following: 
reduction of intake of sugar-sweetened beverages, increased fruit and vegetable consumptions, 
limited screen time to two hours, reduction of trips to restaurants, appropriate portion sizes, 
limited intake of energy-dense foods, and encouragement of participation in moderate to 
vigorous exercise for sixty minutes a day (Gephart & Loman, 2013).  Another successful study 
utilized group interventions that focused on: adherence to diet, improved food choices, meal 
planning, choice of healthier options while eating out, and healthy snack options (Centorrino et 
al., 2006).  Group members made trips to the grocery store together, sampled healthy, easy-to-
prepare meals, and participated in individualized fitness training (Centorrino et al., 2006).  
Mindful eating is another technique that has been studied in families and focuses on slowing the 
pace of eating, removal of distractions while eating, awareness of internal cues of hunger and 
satiety, removal of positive and negative judgements from food, and reduction of emotional 
eating (Knol et al., 2016). 
Practice Guideline Recommendations  
 
Evidence-based guidelines can assist psychiatric healthcare providers in the assessment, 
treatment, and monitoring of metabolic side effects in children and adolescents diagnosed with a 
BSD who are taking AAPs.  Implementation of guidelines can increase the accuracy of 
assessment and diagnosis, guide treatment and planning, and prevent long-term complications of 
metabolic side effects of AAPs (Koch & Scott, 2012).  Monitoring of side effects can also 
identify other complications or undiagnosed conditions such as diabetes, hypertension, and 
hyperlipidemia (Ronsley, Raghuram, Davidson, & Panagiotopoulos, 2011).  However, most 
practice guidelines at this time do not offer specific medication recommendations for a patient by 
phase of the illness or at the severity level of symptoms (Kumra et al., 2008).   
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 There are four practice guidelines in publication that relate to the population affected by 
this practice problem (Appendix C).  These particular guidelines were selected due to their 
relevance to the assessment, treatment, and management of metabolic side effects.  The 
guidelines were reviewed and critiqued based on their content, grounding in evidence-based 
research, and feasibility and applicability to this particular patient population.  Though some 
guidelines have not been updated recently, the foundational information contained in these 
guidelines is still relevant and pertinent to the purpose of this project. Interventions based on 
these guidelines can improve practice and thereby improve outcomes for this vulnerable 
population.  
The Practice Parameter for the Assessment and Treatment of Children and Adolescents 
with Bipolar Disorder by the American Academy of Child and Adolescent Psychiatry 
(McClellan, et al., 2007) outlines recommendations for the assessment and treatment of pediatric 
patients diagnosed with a bipolar disorder.  This guideline includes a synthesis of the literature, 
epidemiological statistics, disease prevalence and a definition of key terms in regard to the DSM-
IV-TR. Included in these guidelines are the risk factors for the development of a bipolar disorder, 
its clinical presentation, and the controversy surrounding use of this diagnostic label in the 
pediatric population.  Treatment recommendations for pharmacological and nonpharmacological 
interventions, including Electroconvulsive Therapy (ECT) are outlined based on studies mostly 
conducted in adults. General guidelines for monitoring symptoms and side effects are included.  
While the evidence and specific recommendations of this guideline are dated, the key themes of 
proper diagnosis, appropriate treatment with both pharmacological and nonpharmacological 
interventions, and ongoing monitoring of symptoms and side effects are still applicable today. 
  
 
 
15 
The second guideline reviewed was the Practice Parameter for the Use of Atypical 
Antipsychotic Medications in Children and Adolescents by the American Academy of Child and 
Adolescent Psychiatry (Findling et al., 2011).  This practice guideline is specific to pediatric 
patients who have been prescribed AAPs and provides recommendations for treatment and 
monitoring.  Each AAP medication is described and includes the findings of studies conducted 
on that medication, approved indications, target symptoms, and possible side effects (Findling et 
al., 2011).  Although the consistency of information for each medication is lacking, specific side 
effects and safety concerns are delineated and defined. Other medication information provided 
includes: suggestions for baseline and continuous monitoring and assessments, dosing 
recommendations, steps to take if side effects occur, the use of multiple AAPs and other 
psychotropic medications simultaneously, treatment trajectory and discontinuation, and what to 
do in cases of treatment failure.  This guideline gives special attention to the monitoring of body 
mass index (BMI), weight, blood glucose, lipids, movement disorders, prolactin levels, heart 
rate, blood pressure, and electrocardiogram (ECG) changes.  While this guideline is more recent 
and specific than the first guideline above, it does not give specific recommendations for the 
timing of lab work and vital signs.  Again, because of the age of the literature, recent studies and 
evidence for newer AAPs is not included.  Drug-specific recommendations are given for 
clozapine, quetiapine, and ziprasidone (Findling et al., 2011).   
The third guideline was developed by the Consensus Development Conference on 
Antipsychotic Drugs and Obesity and Diabetes by the ADA, APA, AACE, and NAASO (2004).  
This guideline was developed due to the recognition of the relationship between AAPs and 
obesity, diabetes, dyslipidemia, and cardiovascular disease.  It uses evidence from the findings of 
studies to hypothesize possible mechanisms for metabolic disturbances.  Metabolic parameters in 
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this guideline include assessing personal and family history of cardiac and metabolic disorders, 
weight, BMI, waist circumference, blood pressure, fasting blood glucose, and a fasting lipid 
panel at baseline and at regular intervals.  Providers are also encouraged to educate patients and 
family members on signs and symptoms of diabetes (ADA et al., 2004).  Nutrition and physical 
activity counseling in general are recommended and possible alternative treatments are suggested 
(ADA et al., 2004).  The limitations of the guidelines and future research needs are also 
described (ADA et al., 2004).  This guideline does not include specific interventions for dealing 
with metabolic side effects other than referral to a specialist and/or switching to another 
antipsychotic.  It is also does not provide recommendations specific to the pediatric population.  
The taskforce does recognize that more research is needed to show that early metabolic changes 
are precursors to long-term implications and whether or not the metabolic changes are due to the 
medications or the disease process itself (ADA et al., 2004).  The age of this guideline and the 
arrival of new medications can be factors in the lack its implementation by providers.  
The fourth practice parameter reviewed was the Prevention and Management of Obesity 
for Children and Adolescents by the Institute for Clinical Systems Improvement (Fitch et al., 
2013).  While this guideline does not directly address cases of pediatric bipolar disorders and 
weight gain related to the use of AAPs, it provides comprehensive and specific interventions for 
prevention, assessment, and management of obesity.  Recommendations are grouped by 
intervention level and the quality and strength of the recommendation.  Specific points of 
teaching are given that can be easily employed during the appointment including, but not limited 
to, eating dinner together as a family, limiting screen time to two hours or less a day, and eating 
breakfast daily.  Recommendations are given for diet changes, physical activity, sleep, and 
pharmacological, nonpharmacological, and surgical interventions.  Screening and assessment 
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techniques are broken down by age group and body system and identification of comorbidities is 
discussed with symptoms, potential consequences, and assessment findings (Fitch et al., 2013). 
Algorithms for laboratory monitoring provide clear instructions for assessment and follow-up of 
patients on AAPs (Fitch et al., 2013).  A section on assessing the patient’s readiness for change 
using the Transtheoretical Model of Change is included (Fitch et al., 2013).  Strategies for 
implementation address patient, provider, and system barriers (Fitch et al., 2013).  Links to high 
quality Web resources such as HealthPeople.gov and ChooseMyPlate.gov and growth charts are 
given as well (Fitch et al., 2013).  The comprehensiveness of this guideline and its extensive 
length are both facilitators and barriers to its feasibility.  While much information is included that 
could aid mental health providers in assisting patients with weight loss, the lack of perceived 
responsibility to provide this education could prevent its implementation.  This guideline is quite 
lengthy, which could impact the feasibility of implementation. 
Barriers to Use of Practice Guidelines  
 
There are numerous individual and organizational factors that contribute to the gap 
between the actual care delivered and the recommended care in a practice guideline.  Individual 
barriers for providers to implement a guideline includes time constraints, personal attitudes, and 
years of practice experience.  Organizational factors that may limit the implementation of 
guidelines includes the lack of referral systems and appropriate equipment.  Finally, patient 
characteristics may be a barrier to implementation due to embarrassment, co-pay requirements, 
and transportation needs (Fagiolini, 2008; Jeffrey, 2015; Ronsley et al., 2011; Suppes et al., 
2007; Taba et al., 2012; Teeluckdharry et al., 2013).   
Provider Barriers.  Lack of time is identified by providers as the largest barrier in 
adhering to assessment, treatment, and monitoring guidelines.  Providers report having 
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inadequate time to review guidelines, perform assessments, interpret lab values, and educate 
patients on possible metabolic side effects, monitoring guidelines, diet, exercise, and lifestyle 
changes (Fagiolini, 2008; Jeffrey, 2015; Ronsley et al., 2011; Suppes et al., 2007; Taba et al., 
2012; Teeluckdharry et al., 2013).  Provider comfort level with conducting assessments, 
particularly with measurement of waist circumference is another important factor (Fagiolini, 
2008; Jeffrey, 2015; Sernyak, 2007; Sugawara et al., 2014; Walter et al., 2008).  
The provider’s opinion about the guidelines and experience level can impact adherence 
(Khan et al., 2010; Teeluckdharry et al., 2013).  Some find the recommendations impractical, 
wasteful, expensive, not applicable to their patients, inconvenient and/or too involved or 
complex (Khan et al., 2010; Sernyak, 2007; Taba et al., 2012; Walter et al., 2008).  Some mental 
health providers do not feel that it is their responsibility to monitor metabolic parameters or that 
the psychiatric symptom management take precedent over physical health problems (Khan et al., 
2010; Ronsley et al., 2011; Teeluckdharry et al., 2013; Walter et al., 2008).  Other providers are 
concerned that providing more education on potential metabolic side effects to their patients will 
have a negative effect on treatment adherence (Ronsley et al., 2011).  Providers with less 
experience are more likely to adhere to practice guidelines, possibly due to the inclusion of 
practice guidelines in their education program (Suppes et al., 2007; Taba et al., 2012). Younger 
providers are also more likely to have a positive outlook regarding guidelines and find them easy 
to access and use (Taba et al., 2012) 
Organizational Barriers.  There are also barriers at the level of the organization. 
Limited accessibility of primary care providers (PCPs) and lack of developed referral systems 
contribute to inadequate follow-through by the patient, provider, and/or office staff with regards 
to lab work and other recommendations (Jeffrey, 2015; Sernyak, 2007; Velligan et al., 2013).  
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Limited access to appropriate anthropometric equipment can also be an issue, especially for 
smaller offices (Jeffrey, 2015; Ronsley et al., 2011).  Others site lack of reimbursement, staff 
availability, and resistance to change as reasons for noncompliance (Jeffrey, 2015; Sernyak, 
2007; Velligan et al., 2013).   
Large facilities may have access to additional resources needed to implement practice 
guidelines, including staff members and technology, for intervention development, 
implementation, data collection, and compliance auditing (Khan et al., 2010).  It is labor-
intensive to follow metabolic monitoring guidelines and involves the completion of multiple 
steps (Velligan et al., 2013).  It may be difficult for offices that are under-staffed with limited 
working capital to comply with the practice recommendations (Sernyak, 2007; Velligan et al., 
2013).   
The evidence is contradictory regarding the use of practice guidelines in hospital settings 
as compared with private practice settings.  There is some support for greater use by providers in 
hospital settings who were more likely to measure metabolic parameters, prescribe medications 
for metabolic derangements, and discontinue medications if metabolic side effects occurred 
(Suppes et al., 2007).  There is some evidence that outpatient offices are more likely to 
experience barriers related to lack of resources including time and lack of established protocols 
(Sernyak, 2007; Taba et al., 2012).  Yet, in contrast, Perlis (2007) found that community mental 
health practices were more likely to use practice guidelines and that those in the hospital setting 
were more likely to cite lack of time as a barrier to their use.   
Patient Barriers.  Other studies identify patient fear of needles, co-pay requirements, 
and lack of system support as potential barriers to adherence (Fagiolini, 2008; Khan et al., 2010; 
Sernyak, 2007; Teeluckdharry et al., 2013).  Patient embarrassment with having weight and 
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waist circumference measured can also be a barrier.  Difficulties with access to transportation to 
appointments or to the lab can impact patient adherence to recommendations.  The patient may 
also lack access to a PCP, specialist, nutritious food, and/or exercise facilities.   
Practice Change Interventions 
 
 Metabolic monitoring recommendations have been developed and studied by several 
researchers to improve provider compliance with practice guidelines.  While the 
recommendations vary in the extent of their development, content, and delivery, most focus on 
increased frequency of monitoring of vital signs and metabolic-related laboratory values.   
Velligan et al. (2013) argued that knowledge of guidelines and expectations of compliance with 
guidelines are not enough to change practice.  Strategies to facilitate use of practice guidelines 
include: focusing on early intervention and wellness, accounting for possible barriers to their 
implementation, improving awareness of the symptoms of diabetes and cardiovascular disease, 
and increasing awareness of the guideline recommendations through the use of evidence-based 
standards (Sernyak, 2007).   
Implementation of guidelines must be tailored to fit the clinical setting (Velligan et al., 
2013).  Key to implementation is the establishment of responsibility for who monitors and 
coordinates care.  Successful implementation of practice guidelines requires buy-in from the 
providers that monitoring is of value, a plan for monitoring, dissemination of the results, and for 
follow-up treatment (Sernyak, 2007).  User-friendly, standardized assessments and order forms 
and provision of in-house lab draws can reduce potential barriers to implementation (R. Reeves 
et al., 2009; Ronsley et al., 2011; Velligan et al., 2013).  Development of referral networks and 
collaboration with family physicians, endocrinologists, dieticians, and pharmacists can improve 
care for and monitoring of patients on AAPs (Khan et al., 2010; Sernyak, 2007).   
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Researchers at the New Jersey Department of Corrections incorporated an evidence-
based monitoring protocol for inmates receiving AAPs (R. Reeves et al., 2009).  The protocol 
included a revised progress note with designated sections for documenting personal and family 
history of risk factors, frequency intervals for specific metabolic monitoring protocols, clickable 
boxes for easy ordering of tests, and a user-friendly flowsheet to show changes in values over 
time (R. Reeves et al., 2009).  The program developers utilized key factors that proved to be 
essential to the success of the project which included support of facility leadership, program 
prioritization and management, clear roles and assignments, deliberate implementation of the 
program, collaboration with nursing staff, and individual and management-level follow-up (R. 
Reeves et al., 2009). 
A study at Veteran Affairs facilities in the United States utilized computer-based 
reminders, a poster display of monitoring and management recommendations, an automated 
computer system to identify patients due for initial metabolic monitoring, and a 
psychoeducational weight management program for patients (Owen et al., 2013).  Assessment of 
organizational climate and readiness to change, identification of key staff members and 
stakeholders to facilitate the implementation of the program, and provider feedback regarding 
performance were included in the program (Owen et al., 2013). 
A program evaluation in Texas employed the development of a new position called the 
Medical Assistant for Metabolic Monitoring who was responsible for ensuring that lab work and 
vital signs were collected, reviewed by the physician, and placed on the chart (Velligan et al., 
2013).  The findings of Velligan and others (2013) emphasized the importance of educating 
employees about the guidelines, who was responsible for each task, normal and abnormal lab 
values, and how to respond to lab values that were out of range.  The research team also used 
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their computer system to identify patients who were in need of metabolic monitoring who also 
had appointments within the next week (Velligan et al., 2013).   
Practice Toolkits.  Care bundles or practice toolkits are quality improvement 
interventions that focus on improved quality of care through utilization of evidence-based 
practices and improved compliance with the guidelines (Clarkson, 2013; Yamada, Shorkey, 
Barwick, Widger, & Stevens, 2015).  Use of guidelines and practice bundles have been shown to 
improve quality of care in other areas of medicine such as ventilator care, care of central lines, 
and treatment of sepsis (Taba et al., 2012; Wiechers et al., 2012).  There are very few studies that 
critique the effectiveness of the practice toolkit as a quality improvement intervention (Yamada 
et al., 2015).   
Existing evidence supports practice toolkits can increase provider adherence to practice 
guidelines, but certain measures should be taken during the planning, implementation, and 
analysis phases to ensure high validity success (Yamada et al., 2015). Toolkits that contain 
superfluous steps, and/or include components that are not evidence-based can be difficult to 
implement (Clarkson, 2013).  Introduction of too much information at one time, attempting to 
measure multiple outcomes with one project, and having a quality improvement project that is 
too complex are pitfalls to avoid with the introduction of toolkits.  The interventions should have 
clear goals identified, should be based on evidence, and tailored to the environment (Yamada et 
al., 2015).  Each piece of the toolkit should be based on high level evidence and its rationale for 
inclusion should be clear (Yamada et al., 2015).  To avoid the common mistake in previous 
studies using toolkits, the outcome measures should demonstrate that the intervention is 
responsible for the changes (Yamada et al., 2015).   
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The findings of two recently published systematic reviews recognized that many of the 
individual studies failed to attribute the success of the intervention to the toolkit itself (Barac, 
Stein, Bruce, & Barwick, 2014; Yamada et al., 2015).  In some of the studies, the toolkits were a 
part of a larger intervention and the impact of the toolkit alone may not have been reflected in the 
outcome measures. Additionally, the individual pieces of the toolkit were not consistently 
analyzed so the success or failure of that part of the toolkit could have affected the overall 
outcome (Barac et al., 2014; Yamada et al., 2015).  
Strengths and Weaknesses of Existing Research and Utility of Research 
 
There are several strengths in the existing research.  Multiple studies have rendered 
similar results when comparing the level of knowledge of monitoring recommendations to actual 
practice.  There have been studies across different settings and with providers who treat various 
age groups.  Study participants are diverse in training and years of experience, giving a more 
comprehensive sample.  Existing research can be used to tailor interventions to increase use of 
monitoring guidelines to fit the local setting. Barriers discussed in existing studies can be used 
preemptively to identify possible solutions.  
Weaknesses in the existing literature include reliance on self-reporting of behaviors, 
conflicting data, and high variability of interventions, which makes comparison difficult.  Some 
studies show conflicting data when in comparison of providers in certain practice settings, and 
comparison of providers based on years of practice.  There is also a lack of consensus on the 
definition of metabolic syndrome.  Most sources agree that metabolic syndrome includes 
abdominal obesity, elevated triglycerides, low high-density lipoprotein levels, and elevated 
fasting glucose.  There is less agreement on the exact laboratory measurement ranges, the 
number of required symptoms, and if other measures such as microalbuminuria, coagulation 
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abnormalities, and/or presence of polycystic ovarian syndrome should be included or excluded 
(R. Reeves et al., 2009).  Some question whether these symptoms are as or more significant 
collectively than the individual measures.  
 The results of studies about provider adherence to metabolic monitoring 
recommendations vary widely.  There is also inconsistency in the variables studied.  Some look 
at baseline monitoring at the time of treatment initiation and at regular intervals during treatment.  
These intervals differ in their frequency across studies.  Other studies also look at other factors 
such as if the labs ordered by the physician were completed, documented in the chart, and 
viewed by the physician at completion.  Inclusion of all these steps is important because it is not 
enough to order the labs, but to also follow through and take the necessary steps to ensure proper 
intervention. (Velligan et al., 2013).  Many of the studies use self-report of monitoring practices 
by the providers which data suggests may be an overestimation when compared to actual 
practices (Suppes et al., 2007). 
While the research findings can be useful, there are also concerns related to the feasibility 
of interventions to increase use of guidelines.  High variability in practice sites can make 
implementation of these programs difficult.  In a study conducted in the outpatient setting in 
Texas, staff members of the intervention clinic could not keep up with the demands of the 
metabolic monitoring program and also continue to complete other duties (Velligan et al., 2013).  
For a program to be successful it should be financially feasible and expectations of staff 
members should be reasonable.  
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CHAPTER 4: CONCEPTUAL MODEL 
 Ronald Havelock’s (1970) Theory of Planned Change Model guides the design and 
implementation of this project.  Havelock’s model involves change agents to facilitate change.  
This model identifies four roles of a change agent – catalyst, solution giver, process helper, 
resource linker (Havelock, 1970).  Identification of change agents who can fulfill these roles 
fosters the success of the project.  These change agents will encourage the intervention, offer 
solutions to problems that arise, aid in the flow of the implementation, and who have access to 
the necessary resources provide critical support.  This may take the form of one or more people 
within the setting.  Additionally, the presence of these change agents at different levels of the 
organization further increases the potential for success of the project.  
This model is comprised of six steps: build relationships, diagnose the problem, acquire 
resources, choose a solution, gain acceptance, and stabilize the change (Havelock, 1970).  These 
steps are addressed in this project’s setting.  It was anticipated that the existing relationship 
between the author who is a practicing provider at one of the sites of implementation would 
facilitate building relationships around a new initiative.  The recruitment of an additional DNP-
prepared practitioner to serve on the project committee also assisted with the building of the 
relationship.  The problem identification was achieved through recognition of the lack of practice 
guideline use to address a common practice problem.  Resources are acquired through 
stakeholder involvement and analysis of the population and practice sites.  Involvement of 
management assisted in acquiring resources necessary to carry out the plan.  A solution was 
chosen based on evidence-based research.  Involving stakeholders in the planning and 
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implementation of the project and soliciting their recommendations during the assessment of the 
project were used to increase acceptance.  The change can be stabilized through consistent 
implementation, data analysis, and modifications as needed.  
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CHAPTER 5: METHODOLOGY 
 This project was a practice change initiative that implemented a toolkit developed from 
the evidence and customized for this setting.  The toolkit provided direction for practice change 
to improve metabolic outcomes in child patients receiving AAPs.  The practice change initiative 
required several phases and its full implementation was beyond the scope of the DNP project.  
All Phases of the practice change are identified in Appendix R.  This project focused on 
implementation of Phase I.  The steps for Phase I included: provider and staff education, 
implementation of the toolkit focusing on vital sign and BMI measurement and ordering of 
metabolic labs, and data collection and analysis.  
Setting 
 
The setting consisted of a private, outpatient mental health office located in a small city 
in Western North Carolina.  The system is comprised of insurance providers, referring offices, 
pharmacies, hospitals, and laboratory collection centers.  The characteristics of these components 
influenced the design, implementation, and effectiveness of the project. Due to the overall deficit 
of mental health settings in the region, this office serves patients from five counties, as well as 
patients who travel from a neighboring state.  The office is accessible by limited public 
transportation and private vehicle.  New patient appointments are allotted 45 minutes and 
established patient appointments are allotted 15 minutes. Due to a high number of patient no-
shows, patients are frequently double-booked for the same time slot.  Documentation is 
completed using written assessments or dictation services; not all assessments are performed 
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using standardized templates or forms.  Electronic medical management software is used only for 
billing and scheduling purposes.   
Referrals come from local primary care offices, inpatient units, crisis stabilization units, 
hospital emergency departments, mobile crisis community teams, case managers, and other 
community organizations and facilities.  Laboratory offices and outpatient laboratory services 
through local hospitals are located near the office, some within reasonable walking distance.  
Urine drug screening is the only laboratory service available at the office.   
Practice Change Participants 
 
Providers at this practice include: a Doctor of Osteopathic Medicine (DO), two 
Psychiatric-Mental Health Nurse Practitioners (PMHNP), and a Physician Assistants (PA).  
These providers vary in their experience and years of practice ranging from a new-graduate 
PMHNP in his first year of practice to more than 40 years of experience for the DO.  Other staff 
members include substance abuse therapists, office assistants, laboratory staff members, an 
office manager, and the directors of the clinic. 
Stakeholders 
 
Employees with greater receptivity to change were used as key stakeholders and role-
models for those who were more resistant.  Relationship-building to support this practice change 
was key for success.  The participants in this project included people of diverse educational 
backgrounds and roles within the organization; therefore, it was imperative to have key 
stakeholders for each level of employee.  To build relationships and gain acceptance, it was 
important to understand current job roles, clarify each member’s role in the practice change 
initiative, identify interaction between roles, and understand how roles would be impacted by the 
practice change.  Providers who were more open to quality improvement projects were used as 
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early adopters in hopes of encouraging other providers to participate.  Those in management 
positions were key to the success of the project through demonstration of their support for the 
initiative.  Managerial support occurred by ensuring providers had the proper equipment 
necessary for the completion of the assessments, verbalizing support of quality improvement 
efforts, and following up with providers regarding their participation.  This project highlighted 
the need for evidence-based practice and quality improvement initiatives for those in all 
positions.  There is not a person in the office designated to oversee quality improvement; 
therefore, discussion with management of the importance of quality improvement projects was 
important.  Collegial discussion promoted relationship-building and created an opportunity to 
recognize the need for improvement.  Stakeholders expressed interested in implementation of the 
project to raise the quality and safety of care.  
Ethics and Human Subjects Permissions 
 
This practice change project was submitted to the Office of Human Research Ethics at the 
University of North Carolina at Chapel Hill.  It determined by this office that this submission did 
not constitute human subjects research as defined under federal regulations and did not require 
Institutional Review Board (IRB) approval.  
Recruitment 
 
All providers and involved staff members were encouraged to participate in the project 
implementation.  Ideally, the project would be implemented with all patients who met the 
criteria.  The providers had the ability to implement these assessments and interventions without 
the use of the toolkit contents; therefore, there was not an ethical dilemma if the provider failed 
to adapt to the practice of toolkit use. 
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Toolkit Development 
 
The evidence supports toolkits can be effective in improving provider adherence to 
guidelines while addressing some of the barriers discussed previously (Clarkson, 2013; Yamada 
et al., 2015).  A toolkit was developed and implemented as a guideline and to provide structure 
and reminders for best practice.  This site relies on paper records. Without the standardization of 
electronic documentation with associated alerts, limited treatment time, and range of provider 
experience, consistent evidence-based practice often presented a challenge.  Due to the scope of 
the toolkit and the culture of the practice change setting, it was planned to introduce the toolkit in 
three phases.  Phase I was introduced and included recommendations based on the Consensus 
Development Conference on Antipsychotic Drugs and Obesity and Diabetes by the ADA, APA, 
AACE, and NAASO (Appendix A) (2004).  Phase I toolkit contents included the following 
resources:  
• practice guideline recommendations (Appendix A) 
• standardized personal and family metabolic history assessment (Appendix D) 
• laboratory documentation form based on recommended schedule (Appendix E) 
• vital sign documentation form (Appendix F) 
• standardized laboratory ordering forms (Appendix G) 
• normal laboratory ranges (Appendix H) 
• preprinted referral forms for primary care providers and specialists (Appendix I) 
• release of information form 
• patient/caregiver education handout (Appendix J) 
• list of tasks and the staff responsible (Appendix K) 
• audit tool (Appendix L) 
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• communication checklist (Appendix M)  
• interventions documentation form (Appendix N) 
• tips for using the measuring equipment properly (Appendix P) 
The information was organized in a file folder and assembled by office support staff.  
Each provider had a supply of pre-made folders in his or her office.  From a workflow 
perspective, toolkit availability would eliminate time and effort required to locate the necessary 
resources.  Other resource forms provided in Phase I of the project were included for the 
provider’s convenience for reference and were not measured for compliance during the initial 
phase. For example, information regarding location of laboratory testing was also included in the 
toolkit so providers would know where to direct the patient for those ancillary services 
(Appendix G).  The extra resources were included to streamline the process of information 
seeking.  The goal was to facilitate the incorporation of best practices through use of the toolkit 
to complete the desired tasks.  
Provider and Staff Education 
 
The toolkit was introduced to providers and other staff members during a staff meeting 
outside of business hours to allow for adequate time to review the contents and to ask questions 
if necessary.  The staff meeting allowed providers and other staff members involved in the 
project’s implementation the opportunity to provide input into the toolkit design and 
implementation before project initiation.  This inclusive meeting encouraged shared decision-
making and was important to gain buy-in of the project.  An explanation of the necessity for this 
intervention and a plan for its implementation was discussed.  During this education phase, it 
was emphasized that the providers have the responsibility to monitor for potential side effects of 
the medications they prescribe (Sernyak, 2007).  The project process and flow were explained.  
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All participants were given a handout that contained a summary of the literature review, the 
proposed project, the proposed methodology, data collection methods, outcome measures, 
timeline of implementation, and a sample toolkit.  
Due to constraints of allotted time for appointments, providers were encouraged to 
consider review of the contents of the toolkit with the patient and caregivers during a separately 
scheduled appointment.  Education was provided about documentation and billing tips for this 
type of appointment.  For example, the appointment could be billed as a follow-up with a therapy 
add-on code due to the amount of time spent discussing interventions and engaging in 
psychoeducation.  Providers were reminded to review the chart at each visit to ensure that proper 
follow-up had taken place.  Roles and responsibilities of staff members were delineated and 
distributed so each staff member and provider understood who was responsible for the execution 
and follow-up tasks within the organization (Appendix K).   
Providers and staff members had the opportunity to practice vital sign measurement with 
the new equipment to ensure knowledge of proper techniques as the staff members and providers 
may be unfamiliar with the equipment. 
The providers and staff members expressed much enthusiasm for the project.  Discussion 
focused on the use of the toolkit with patients other than children taking AAPs, the logistics of 
implementation of the toolkit, and which resource forms might be optional.  One provider voiced 
concerns about how time-consuming implementation of the toolkit would be.  It was emphasized 
for each provider to review the toolkit and attempt implementation so that further concerns could 
be addressed before the project went live. 
Outcomes and Outcome Measures  
 
 Four outcome measures were identified for Phase I of the project:  
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1. The toolkit was employed during the care of patients ages 5-18 years diagnosed with a 
BSD or DMDD who were taking an atypical antipsychotic (new start or continuation)  
a. presence of toolkit contents in the chart 
b. color sticker affixed to outside of chart 
2. Personal and family history assessment of metabolic problems were completed by the 
provider. 
a. completed assessment form in the chart or within the progress note (Appendix D) 
3. Metabolic laboratory studies were ordered at chronological increments recommended by 
the guidelines 
a. documentation of the order by the provider in the visit note or by presence of a 
copy of the order form in the chart (Appendix G) 
4. Vital signs (specifically blood pressure, height, weight, BMI, and waist circumference) 
were taken at chronological increments recommended by the guidelines 
a. documentation of each of the vital signs on the documentation form (Appendix F) 
Implementation Process 
 
After the completion of the education session, the preliminary testing of the toolkit 
began. The implementation timeline can be found in Appendix O.  A toolkit was to be utilized 
upon identification by the provider of a patient within the project population.  A colored sticker 
was included in the toolkit for the provider to affix to the chart.  This allowed for identification 
of the chart during data collection.  The contents of the toolkit were to be added to the patient’s 
chart or given to the patient if applicable.  The providers were to use the practice guideline 
recommendations to order necessary labs, assess vital signs, and perform assessments based on 
recommendations for the specific patient.   
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Plan-Do-Study-Act (PDSA) cycles were used to refine the toolkit contents and 
implementation process.  Cycle 1 consisted of implementation of the toolkit by two providers, 
who utilized the toolkit with two child patients.  Following Cycle 1 minor revisions were made 
based on recommendations from the providers and office staff.  This included reformatting of the 
vital sign documentation form to ensure that there was a designated place to document waist 
circumference.  Other feedback included lack of clarity about which forms were mandatory and 
differences in preference among providers about whether or not to keep in the toolkit reference 
forms that were not mandatory.  These requests were reviewed with the office staff member 
tasked with making the toolkits for the providers and the solution was that toolkits would be 
customized for individual providers.  
After integration of the feedback from Cycle 1, Cycle 2 began with the addition of a third 
provider.  Each of these three providers used the toolkit with three patients.  No revisions were 
recommended after completion of Cycle 2.  A fourth provider was added for Cycle 3. The fourth 
provider did not employ the toolkit with any patients.  This provider reported there was 
insufficient time to do so.  Despite efforts to streamline the process to address individual 
concerns, the provider chose not use the toolkit.  These quick PDSA cycles allowed for fast 
turnaround and were effective in identifying weaknesses. The first three cycles were solely for 
the purposes of toolkit content and process refinement.  The solutions identified from feedback 
after Cycle 1 proved effective for three of the providers and for office staff members.  These 
were presented to all office staff and providers at the conclusion of Cycle 3.  
PDSA Cycles 1-3 prepared the staff and providers for the official cycle - Cycle 4. This 
final cycle included all office staff and providers.  The toolkit was to be utilized with all patients 
within the project population. Data for adherence rates was collected in Cycle 4.  
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CHAPTER 6: DATA COLLECTION AND DATA ANALYSIS 
 A pre-implementation collection of data using chart audits took place to obtain a 
numerical baseline for the outcome measurements.  An audit tool was used to assist in the chart 
audit (Appendix L).   
 
Table 1: Summary of Chart Audit Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
A total of 48 charts met the inclusion criteria and were reviewed for the existence or 
absence of the specific outcome measures prior to project initiation.  Data from the baseline chart 
audit showed low rates of compliance (Appendix Q).  Fasting plasma glucose and fasting lipid 
profile labs were current on only 8.3% of patients.  BMI measurements were completed on 
27.1% of patients.  Vital signs (blood pressure, pulse) were completed on 89.6% of patients, the 
highest rate of compliance.  None of the charts audited during the collection of baseline data 
showed evidence of a metabolic assessment or waist circumference measurement.  
 
Week 0 
% 
Week 2 
% 
Week 4 
% 
Week 6 
% 
Date of Audit  10/22/17 11/5/17 11/19/17 
Dates Audited  10/9-10/20 10/23-11/3 11/6-11/17 
Outcome Measure     
Fasting Plasma Glucose 8.3 13.3 28.6 33.3 
Fasting Lipid Panel 8.3 13.3 28.6 33.3 
Height/Weight 27.1 53.3 85.7 100 
Vital Signs 89.6 100 100 100 
Waist Circumference 0 6.7 71.4 88.9 
Metabolic Assessment 0 26.7 28.6 33.3 
Sticker on Chart 0 20 42.9 33.3 
Forms on Chart 0 26.7 42.9 33.3 
Number of Charts Reviewed 48 15 7 9 
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This baseline data was shared with stakeholders (office staff and providers) during 
staff/provider meetings prior to project implementation.  Goals for improvement change were 
established by the respective staff or provider.  The office staff identified a goal of 100% 
compliance for documentation of vital signs, height and weight, and waist circumference.  
Providers identified a goal of 100% compliance with ordering lab work, metabolic assessment, 
and 100% compliance of use of toolkit within the project population; and, to also use the toolkit 
with other applicable patients. 
 Measurement of these outcomes were accomplished with the final PDSA cycle (Cycle 4).  
Start and end dates for the final six-week-long PDSA cycle were scheduled after the completion 
of the first three cycles.  Three chart audits were conducted at two-week intervals during this 
final cycle.  The electronic schedule was used to identify patients who fell into the age category 
targeted during this practice improvement project who were seen for an appointment during the 
previous two weeks.  These charts were then reviewed to determine they met the inclusion 
criteria of diagnosis and treatment.  The charts of patients 18 years of age and younger, with a 
diagnosis of a bipolar mood disorder or DMDD, being treated with an atypical antipsychotic, 
were then reviewed for provider compliance with the outcome measures.  
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Graph 1: Compliance Data 
 
It was important that each individual intervention was measured independently in order to 
identify potential barriers and points of failure.  Provider compliance rates were calculated for 
each outcome for individual providers and the practice as a whole.  Outcome measurement data 
was documented using run charts and results were displayed at the completion of each of the 
three chart audits in a central location visible to all staff members (Appendix Q).   
Providers were given their individual rates after each audit to show their individual 
progress and areas for improvement.  Each measure was scored independently and if applicable, 
the results were reviewed to see if components were more likely to completed independently or 
clustered with other outcomes.  
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CHAPTER 7: DISCUSSION AND IMPLICATIONS FOR PRACTICE 
Upon completion of PDSA Cycles, evidence of successful implementation included 
increases in the incidences of compliance with the practice guideline recommendations of 
metabolic history-taking and assessment, laboratory and vital sign monitoring, and appropriate 
follow up.  By the end of the implementation time period, the outcome measures of BMI and 
vital signs reached 100% compliance.  The outcome measure of waist circumference improved 
from 0% to 88.9%.  The completion of a metabolic assessment increased from 0% to 33.3%.   
The use of the standardized metabolic assessment form in the toolkit and the use of the 
sticker for identification was a new practice, therefore there was no baseline data.  Outcome data 
for these two measures increased from baseline to Week 2 and to Week 4 chart audits, then 
decreased during Week 6 audit, for a final rate of 33.3% for both measures.   
The outcome measures for BMI, vital sign, and waist circumference measure were 
clustered together because these measurements were conducted by the same two office members.  
Both outcome measures pertaining to labs appeared to be clustered together possibly because 
they were ordered on the same form.  While possible, it was unlikely that the provider would 
order one lab and not the other at the same time.  In all instances, both laboratory markers were 
ordered together, as indicated by their identical rates of compliance.  While the vital signs, 
height, weight, and waist circumference were listed on the same form, this was not a guarantee 
that they would all be performed.  Along the same line, having the assessment forms, sticker, and 
other toolkit forms in one folder did not translate into the use of the individual parts.  This is 
evident by the variations in rates of compliance for these outcome measures.   
  
 
 
39 
While the qualitative feedback from the providers and office staff members supported the 
use of the toolkit, the variations in compliance with each piece of the toolkit did not demonstrate 
that having these items packaged together made any significant impact on their use.  The 
increased rates of compliance could be attributed to the increased awareness created by multiple 
discussions and visual reminders of the project goals.  Having a standardized metabolic 
assessment and the lab order form included in the toolkit improved compliance rates with each of 
these measures.  While a standardized metabolic assessment is not necessary to be in compliance 
with the practice guideline recommendations, this form served as a visual reminder and allowed 
for quick documentation of the patient’s metabolic and family history. The inclusion of the lab 
order form also served as a visual reminder and increased compliance rates.  The main 
differences in the compliance rates were with who was assigned the task(s).  The office support 
staff members had the highest rates of compliance and the greatest improvement in compliance 
rates for the tasks for which they were responsible (vital signs, height, weight, and waist 
circumference).  Provider experience level did not appear to play a role as both the providers 
with the least and the most years of experience had the lowest rates of compliance.   
During Cycle 3 of the project it was revealed that two providers had requested that an 
office staff member complete the metabolic assessment form.  The office staff member had 
agreed to complete the forms.  The metabolic assessment is a function of a clinically trained 
provider, not of administrative staff.  The purpose of the metabolic assessment and the intent of 
the toolkit were reviewed with the staff member and the two providers.  It was emphasized that 
assessments completed by someone other than the designated person would not be counted as 
compliant during the chart audits.  The providers complied with filling out the assessments after 
the discussion.  These providers reported a lack of time to implement the toolkit as the reason for 
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outsourcing this task.  This incident highlighted the work-arounds that providers may employ. 
The value of relationship-building in the Theory of Planned Change Model was exemplified 
during this exchange: open discussion by staff and providers, honest feedback about 
perceived/actual barriers, and resulting behavior change that supported the practice change.  This 
type of interaction is important to stabilize change.  The use of this particular model was not 
successful with all of the individual providers.  This speaks to the other internal and external 
factors that prevent providers from utilizing clinical practice guidelines, much like those found in 
the literature.   
One of the providers involved had initially been very enthusiastic for the project and 
voiced support for the project and the need for providers to be more accountable for the 
monitoring of metabolic side effects.  Yet, as the implementation ensued, this provider was 
increasingly challenged by timely completion of documentation.  As a result, this provider did 
not employ the toolkit with any patients during the period of data collection.  Discussion with 
this provider (relationship building) revealed the PMHNP role was new and the quantity of new 
patients being seen was overwhelming.  This highlighted an important consideration in the 
implementation of practice change.  Administrative and clinical staff are seldom at the same 
experience level and will likely require different amounts of training and support to effectively 
engage with the change process. Awareness of the differing levels of support was also important 
to ensure stabilization of change. 
Another provider voiced concerns regarding the toolkit at the initial staff/provider 
meeting.  This provider did not provide input during the initial testing and did not complete any 
of the assessments independently.  When challenges with participation in the project by these 
two providers were initially identified, individual changes were made to the contents of the 
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toolkits supplied to these providers.  Only the absolutely necessary forms (metabolic assessment 
form, lab ordering forms, patient education handout, and sticker) were included in their toolkits 
in an effort to secure their buy-in, experience the project as less overwhelming and time 
consuming.  This attempt was unsuccessful, as neither provider implemented the trimmed 
toolkit.   
 When office management realized a provider did not value the outcomes of toolkit use 
and was not going to cooperate or participate in the project, the decision was made to transition 
patients who met the criteria for the project off of this provider’s caseload.  This lack of 
willingness to use the established practice guidelines with the project population was considered 
a quality and safety issue for patient care.  Discussion with office management resulted in a 
solution that maintained high quality and safety for patients and for the office.  This exemplifies 
a management-level decision that promotes effective stabilization of change. 
Despite improvements in compliance rates after the implementation of this practice 
change project, there is still significant room for improvement.  There were changes in practice 
in this setting, but not with every provider, not consistently over time, and not with every patient.  
These outcomes are supported in the literature (Wiechers et al., 2012).  Even though the 
compliance rate in many of the studies improved, the rates were not notably higher.  The design 
of the intervention seemed to account for more patient and organization barriers.  While many 
attempts were made to account for barriers at the provider level, it was impossible to mitigate all 
of them.   
A debriefing with office staff and providers was conducted to review the data results, 
elicit feedback, and determine if more PDSA cycles are needed for Phase I, or if Phase II could 
commence.  The biggest barrier to implementation of Phase I of the toolkit was the lack of time 
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to complete the forms.  Providers felt it was too time consuming to fill out the metabolic 
assessment and order labs, yet no one utilized the suggestion of scheduling a separate 
appointment to focus solely on the toolkit contents.  There was not a particular reason identified 
by providers for not using this strategy.  This feedback from providers was congruent with 
previous studies.  None of the providers verbalized that they did not feel like monitoring 
metabolic parameters was their responsibility nor did they voice concern that monitoring 
metabolic changes would impact treatment but it is certainly possible that they did feel this way 
but did not verbalize it.   
Despite the perceived barriers, all staff and providers believed it was a good idea to have 
this type of project because it kept evidence-based practice in the spotlight and provided 
reminders for safe practice.  This recognition of the value and necessity for practice guidelines 
did not translate into the consistent use of those guidelines.  The disconnect between knowledge 
and behavior is well supported in the literature.  Although use of the Phase I of the toolkit 
contents was not yet sustained, positive feedback included having an actual toolkit with all of the 
necessary information in one accessible folder.  The consensus of the staff and providers was that 
more time was needed to further cement this new process before moving on to Phase II of toolkit 
implementation.  
Future phases of the project will incorporate: a nutrition and activity assessment, side-
effect assessment scales, risk assessments, medication indications, side effect management 
suggestions, educational material describing the illness, treatment options, side effects, and ways 
to manage side effects.  
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CHAPTER 8: STRENGTHS AND LIMITATIONS OF THE PROJECT 
 There were several strengths of this project.  This project was based on high levels of 
research evidence.  It was tailored according to the current resources available at the practice 
location and composition of the setting.  The large quality improvement project was divided into 
smaller phases to avoid overwhelming participants, encourage buy-in, simplify a larger project, 
to avoid measuring too many outcomes at once, and to monitor progress with incremental 
changes before moving on to the next phase.  There was sufficient evidence to demonstrate the 
immediate need for action.  Many of the actions involved in the project required little effort to 
complete.  The contents of the toolkit were evidenced-based and tailored to each provider to 
avoid superfluous steps.  The rationale for the inclusion of each part of the toolkit was explained.  
A reasonable amount of information was introduced at one time and reiterated throughout the 
study.  The outcomes, tasks, and roles, were clearly defined.  The outcome measures were 
measured objectively and not based on self-reported data like some previous studies on provider 
adherence.  The necessary tools and equipment to complete the tasks were readily available and 
in working condition.   
 One major weakness of this project was the insufficient mitigation of the productivity-
focused culture.  It was not enough to encourage the providers to schedule an additional 
appointment.  More could have been done to plan for longer appointment time slots for patients 
meeting the criteria for toolkit use to reduce the impact of time as a barrier.  Other weaknesses of 
the project were related to factors not immediately changeable.  The office had not transitioned 
to electronic charting which affected the implementation and evaluation of the project.  The 
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requirement of a paper-based toolkit lowered its transferability to a similar setting.  There was 
not a way to obtain blood work on site, which may impact patient compliance with fulfillment of 
the provider order and thereby impact compliance with filing and reviewing results. As this 
portion of the project did not focus on interventions for metabolic side effects, the providers may 
not have seen the benefit of the assessments.  
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CHAPTER 9: SUSTAINABILITY 
The cost of this project to the offices was minimal.  One office staff member was 
assigned the task of ensuring that the toolkits were always readily available for providers.  The 
initial cost of purchasing additional measuring equipment was minimal as the office already had 
most of the necessary equipment.  Practice change initiatives can decrease productivity initially.  
This would impact the revenue during the implementation phase.  However, if providers utilized 
the technique of scheduling more frequent appointments to monitor side effects and implement 
interventions, more revenue could be produced for the practice.  Continuous assessment of 
barriers after implementation is imperative to adjust the process as needed.  Feedback from 
office staff members and providers is required for continuous process improvement.  
Identification of issues (diagnosis of the problem) and problem-solving (solutions) of these 
issues leads to improved quality and safety of care and improved health outcomes for these 
patients.  PDSA cycles as additional phases of implementation occur are necessary to assist with 
identification of barriers to implementation and further evaluate the components of the toolkit, 
tailoring the toolkit to the needs of the office.   
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CHAPTER 10: RECOMMENDATIONS FOR THE FUTURE 
For this project, streamlining the process may assist in decreasing the feeling that time is 
a barrier.  Implementation of an electronic medical record could greatly assist in this process.  
Strategic scheduling could also assist with the time barrier.  If patients could be identified in the 
scheduling system, scheduled for a longer appointment that was designated to discuss the toolkit, 
there would not be as much pressure to rush through the appointment.  Strategic interaction with 
office management to provide education about quality and safety as it relates to established 
practice guidelines would improve understanding of potential liability and promote discussion 
about solutions for system change.  
This project highlights several other areas for future study.  Because of the seriousness of 
the potential side effects and long-term consequences, there are ethical concerns regarding 
standards of care and safe practice by providers.  Those in management roles need guidance in 
addressing these issues with their employees to maintain high quality and safe care delivery.  
Other studies could look at cost-models like those used in the treatment of asthma to explore the 
creation of protocols that would include the addition of a nurse to the practice who could execute 
standing orders and assist with following practice guidelines.   
Future studies will be necessary to conclude if process improvements translate to patient 
outcome improvements.  Providers often have concerns with time requirements for the use of 
guidelines as well as the amount of time they take to develop and the frequency with which they 
are updated (Taba et al., 2012).   
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This is of particular concern regarding the currency of guidelines that include recommendations 
for newer AAPs that come to market. Given this evidence, there are ample opportunities for 
future research in the problem itself, and in the practice changes to solve the problem.  
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APPENDIX A: MONITORING PROTOCOL FOR PATIENTS ON SGAS 
  
Monitoring Protocol for Patients on SGAs* 
 
 
Baseline 
4 
Weeks 
8 
Weeks 
12 Weeks Quarterly Annually 
Every 5 
Years 
Personal/Family 
History 
X     X  
Weight (BMI) X X X X X   
Waist Circumference X     X  
Blood Pressure X   X  X  
Fasting Plasma 
Glucose 
X   X  X  
Fasting Lipid Profile X   X   X 
Note. SGA = Second-Generation Antipsychotics; BMI = Body Mass Index. 
*More frequent assessments may be warranted based on clinical status. 
Adapted from American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association 
for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601. 
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APPENDIX B: DATABASE SEARCH STRATEGY 
 
Date Search Engine Search Terms Search Limits Results 
9/18/16 CINAHL 
Atypical antipsychotic* OR second generation 
antipsychotic* AND discontinua*AND (child* OR 
adolescen*) 
Sept 2006 – Sept 2016, 
English 
1,150 
9/18/16 PubMed 
(Atypical antipsyhotic* OR second generation 
antipsychotic*) AND discontinua* AND (child* 
OR adolescen*) 
 36 
9/18/16 PsycINFO 
Atypical antipsychotic* OR second generation 
antipsychotic* AND discontinua*AND child* OR 
adolescen* 
2006-2016, English 
210,398 
 
9/18/16 CINAHL 
weigh* AND gain* AND child* OR adolescen* 
AND consequenc* OR effec* 
Sept 2006 – Sept 2016, 
English, all child (age) 
101,449 
 
9/18/16 CINAHL 
weigh* AND gain* AND child* OR adolescen* 
AND consequenc* OR effec* AND iatrogen* 
Sept 2006 – Sept 2016, 
English, all child (age) 
5,438 
9/18/16 CINAHL iatrogen* ANDweigh* AND gain* 
Sept 2006 – Sept 2016, 
English 
12 
9/18/16 CINAHL 
weigh* AND gain* AND child* OR adolescen* 
AND consequenc* OR effec* AND iatrogen* OR 
adverse 
Sept 2006 – Sept 2016, 
English, all child (age) 
45,794 
 
9/18/16 CINAHL 
weigh* AND gain* AND child* OR adolescen* 
AND atypical antisphyschotic* OR second 
generation antipsychotic* 
Sept 2006 – Sept 2016, 
English, all child (age) 
1,909 
 
9/18/16 CINAHL 
side effect* OR adverse AND effect* OR 
consequence* AND treatment* OR relationship 
Sept 2006 – Sept 2016, 
English 
361,696 
 
9/18/16 CINAHL 
patient AND attitude OR percep* AND treatment 
AND compliance OR adherence 
Sept 2006 – Sept 2016, 
English 
75,874 
10/1/16 Clinical Key Weight atypical antipsychotic  2,980 
10/1/16 Clinical Key Weight atypical antipsychotic Guidelines, full text articles 1690 
10/1/16 Clinical Key diet exercise weight child* adolescent Guidelines, full text articles 1947 
10/1/16 Clinical Key diet exercise weight child* adolescent parent Guidelines, full text articles 1330 
10/1/16 Clinical Key 
diet exercise weight child* adolescent atypical 
antipsychotic 
Guidelines, full text articles 90 
10/1/16 Joanna Briggs 
“weight management” OR diet OR exercise AND 
child* OR adolsce* 
 113 
10/1/16 PubMed 
diet OR exercise OR "weight management" AND 
child* OR adolescen* AND parent* AND theor* 
 4394 
10/15/16 
National 
Guideline 
Clearinghouse 
Atypical antipsychotic  27 
10/15/16 
National 
Guideline 
Clearinghouse 
Second generation antipsychotic  53 
10/15/16 
National 
Guideline 
Clearinghouse 
Bipolar AND children  28 
10/15/16 TRIP Bipolar disorder children adolescents Guidelines  210 
10/15/16 PubMed bipolar disorder* children adolescent* 
Guidelines, practice 
guidelines 
17 
10/15/16 CINAHL Bipolar AND children OR adolescen* 
Practice guidelines, 2006-
2016 
1 
10/25/16 PubMed 
(((((((((((provider*) OR prescribe*) OR clinician) 
OR physician) OR practitioner) AND complian*) 
OR use) OR utiliz*) AND lab*) OR monitor*) 
AND atypical antipsychot*) OR second generation 
antipsych 
 631 
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APPENDIX C: SUMMARY OF FOUR PRACTICE GUIDELINES SUMMARY FOR 
CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER 
 
Guideline Target 
Population 
Focus Contents Limitations 
Practice 
Parameter for the 
Assessment & 
Treatment of 
Children & 
Adolescents with 
Bipolar Disorder 
(McClellan, et 
al., 2007) 
Children and 
adolescents 
with a bipolar 
disorder  
Assessment 
and treatment 
Historical context, 
epidemiological 
statistics, prevalence; 
risk factors; clinical 
presentation; screening, 
diagnosis, and treatment 
recommendations; 
monitoring symptoms 
and side effects 
Based on DSM-IV-
TR criteria, vague 
and generic 
recommendations, 
based on studies 
conducted in adults, 
the age of the 
guideline, lengthy, 
dense guideline 
Practice 
Parameter for the 
Use of Atypical 
Antipsychotic 
Medications in 
Children & 
Adolescents 
(Findling, et al., 
2011) 
Children and 
adolescents  
Prescribed 
atypical 
antipsychotic 
medication 
Recommendations for 
treatment and 
monitoring; breakdown 
of AAPs (study results, 
indications, target 
symptoms, side effects); 
recommendations for 
interventions in the case 
of side effects 
Age of the guideline, 
vague and generic 
recommendations, 
based on studies 
conducted in adults, 
lacking information 
on newer 
medications 
Consensus 
Development 
Conference on 
Antipsychotic 
Drugs & Obesity 
& Diabetes 
(ADA, et al., 
2004) 
Adults  AAPs and 
metabolic 
side effects 
Discussion of the 
relationship between 
AAPs and physical 
conditions; 
recommendations for 
assessment and 
monitoring of metabolic 
side effects; nutrition 
and physical activity 
counseling 
recommendations 
Age of the guideline, 
vague and generic 
recommendations, 
based on studies 
conducted in adults 
Prevention & 
Management of 
Obesity for 
Children & 
Adolescents 
(Fitch, et al., 
2013) 
Children and 
adolescents 
Obesity Teaching 
recommendations; diet, 
activity, sleep, 
interventions, screening, 
and assessment 
recommendations; links 
to outside resources; 
implementation 
strategies 
Extensive length, 
age of guideline 
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APPENDIX D: METABOLIC ASSESSMENT FORM 
 
Patient Name: ____________________________________ DOB: _________________ 
 
Assessment Date: ________________ 
 
*It is recommended that this assessment be completed at baseline and yearly thereafter when initiating 
treatment with an atypical antipsychotic medication. 
 
Psychiatric Diagnosis(es): 
_________________________________________________________ 
 
Medical Diagnosis(es): _________________________________________________________ 
 
Personal and Family History: 
 
 No Yes Unknown 1st Degree Relative 2nd Degree Relative 
Diabetes  __ Type 1 
__ Type 2 
__ Gestational  
   
Hyperlipidemia      
Cardiovascular 
Disease 
     
Obesity      
 
Risk Factors: 
 
 No Yes 
Smoking   ___ cigarettes/day 
Physical Activity   ___ mins/day 
Screen Time   ___ mins/day 
Sugar-Sweetened 
Beverages 
  ___ cans of soda/day 
___ juice boxes/day 
Fast/Fried Foods   ___ meals/week 
 
 
Adapted from:  BC Mental Health & Substance Use Services (2014).  Metabolic assessment, 
screening, & monitoring tool.  Accessed from http://www.bcchildrens.ca/health-
professionals/clinical-resources/endocrinology-diabetes/atypical-antipsychotics.  
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APPENDIX E: PROVIDER DOCUMENTATION FORM  
 
Use this form to document pertinent lab and vital sign values under the date of collection. 
 
 
Patient Name: ___________________________________  DOB:__________________ 
 
 
Adapted from:  BC Mental Health & Substance Use Services (2014).  Metabolic assessment, 
screening, & monitoring tool.  Accessed from http://www.bcchildrens.ca/health-
professionals/clinical-resources/endocrinology-diabetes/atypical-antipsychotics 
 
 
 
 
 
Date Completed → 
   
 
       Result Documented 
 
Hx Completed          
Weight          
BMI          
Waist Circumference          
Blood Pressure          
Fasting Blood Sugar          
Fasting Total 
Cholesterol 
         
Fasting LDL-C          
Fasting HDL-C          
Fasting Triglycerides           
          
AST          
ALT          
TSH          
Free T4          
Prolactin           
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APPENDIX F: VITAL SIGN DOCUMENTATION FORM 
 
 
Patient Name: ___________________________________  DOB:__________________ 
 
 
Date Waist Circumference Staff Signature Provider Signature 
    
    
    
 
 
 
 
 
 
 
 
 
 
Date Height Weight BMI 
Blood 
Pressure 
Pulse Respirations 
Staff 
Signature 
Provider 
Signature 
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APPENDIX G: LAB ORDER FORM  
 
You are due for LABWORK! 
 
LABCORP 
809 N. Lafayette St. 
Shelby, NC 28150 
Hours: M-F 7:30AM-1:00PM 2:00PM-
4:30PM  
 
640 Summit Crossing Pl Ste 206 
Gastonia, NC 28054 
Hours: M-F 7:30AM-5:00PM 
CaroMont Outpatient Lab  
2555 Court Drive, Ste 120  
Gastonia, NC 28054  
Phone: 704-834-4335  
Hours: M-F 6:30AM-5:00PM  
Carolinas Healthcare System – Kings 
Mountain  
706 West Kings Street 
Kings Mountain, NC 28086  
Phone: 980-487-5000 
 
Carolinas HealthCare System – Cleveland 
 
201 E Grover St. 
Shelby, NC 28150 
Phone: 980-487-3000 
Rutherford Regional Health System 
288 S. Ridgecrest St. 
Rutherfordton, NC 28139 
Phone: 828-286-5123 
 
 
INSTRUCTIONS: 
 
Take this form with you to have the labs completed. 
 
Labs can be drawn at any Lab Corp or Outpatient Lab at your nearest hospital.  
 
Please do NOT eat or drink anything after midnight the night before your blood work is drawn.  
After your visit, you may eat and drink normally. 
 
Please note that failure to have blood work drawn may result in a delay in your medications 
being filled.  Lab work is an important tool in treating you safely and effectively.   
 
Thank you!
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Patient Name: _______________________  DOB: __________ 
 
Date of Order: _____________ 
 
Monitoring Protocol for Patients on AAPs* 
 Baseline  
(0-3weeks) 
4 
Weeks 
8 
Weeks 
12 
Weeks 
Quarterly 
(4-11 months) 
Annually 
Every 5  
Years 
Fasting Plasma Glucose X   X  X  
Fasting Lipid Profile X   X   X 
 
Atypical Antipsychotic Lab Protocol 
(Please circle the lab(s) you wish to order) 
 
Fasting Glucose 
 
Fasting Lipid Panel 
 
 
Other labs:  
 
Prolactin level 
 
Fasting Insulin level 
 
CBC w/ diff 
 
CBC w/o diff 
 
Other(s): _________________________
 
 
 
 
Diagnosis Code(s): _______________________________ 
 
 
Provider Signature: ______________________________        Date: _______
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APPENDIX H: METABOLIC LAB VALUE REFERENCES TABLE 
 
 
Metabolic Lab Value References 
 
Test Specimen Conventional Units SI Units 
Cholesterol 
 
     High-density lipoprotein (HDL-C) Plasma ≥ 40 mg/dL ≥ 1.04 mmol/L 
     Low-density lipoprotein (LDL-C) Plasma ≤ 130 mg/dL ≤ 3.36 mmol/L 
     Total (TC) Plasma 150–199 mg/dL 3.88–5.15 mmol/L 
Triglycerides (desirable level) Serum < 250 mg/dL < 2.82 mmol/L 
Fasting Glucose Plasma 70–105 mg/dL 3.9–5.8 mmol/L 
 
 
Wians, Jr, F. (2017).  Blood tests: Normal values.  Accessed from 
http://www.merckmanuals.com/professional/appendixes/normal-laboratory-values/blood-tests-
normal-values#v8508814. 
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APPENDIX I: REFERAL FORM 
 
 
Date: _____________ 
 
Patient’s Name: _____________________________ DOB: __________   
 
 
From:  Referring Provider: ___________________________  
 
To:    Provider Name: __________________________ Fax Number: _________________ 
 
 
Reason for Referral: _____________________________________________________________ 
 
______________________________________________________________________________ 
 
______________________________________________________________________________ 
 
Attachments: 
 Lab work 
 Note(s)  
 
 
 
Date Referral Sent: _________________  Staff Signature: ______________________ 
 
Appointment Made: __________________ 
 
Additional Notes: _______________________________________________________________ 
 
______________________________________________________________________________ 
 
______________________________________________________________________________ 
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APPENDIX J: PATIENT EDUCATION HANDOUT 
 
Atypical Antipsychotics & Metabolic Monitoring 
 
What are they? 
- Atypical antipsychotics (AAPs) are a class of medication used to treat certain mental health symptoms 
and disorders 
- The most common ones used in children and teens are: 
o Seroquel (quetiapine) 
o Risperdal (risperidone) 
o Zyprexa (olanzapine) 
o Abilify (aripiprazole) 
o Geodon (ziprasidone)
Why are they used? 
- In children and teens, these medications are commonly used to treat symptoms such as: 
o Aggression 
o Mood swings 
o Behavioral difficulties 
o Hallucinations  
 
What are the side effects? 
- Treatment with an atypical antipsychotic may result in side effects 
- Not everyone will experience side effects  
- Side effects may resolve quickly or may persist 
- Potential side effects include, but are not limited to: 
o Changes to blood pressure 
o Weight gain 
o High cholesterol  
o High blood sugar 
o High triglycerides 
o Increased appetite 
o Drowsiness 
 
What is the best way to monitor for side effects? 
- Physical examination  
o Height  
o Weight 
o Body Mass Index (BMI) 
o Waist circumference  
o Blood pressure 
- Blood tests 
o Cholesterol, triglycerides, and blood sugar 
o Before starting and at certain times while taking the medication 
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How can I help? 
- Watch your child for the following symptoms: 
o Frequent urination 
o Feeling more thirsty than normal 
o Feeling much hungrier than normal 
o Feeling tired all of the time for no reason 
- Be sure to tell your provider if a family member has a history of diabetes, stroke, heart attack, high 
blood pressure, or high cholesterol 
 
What is the best way to treat and prevent side effects? 
- Removing or switching AAP medications as advised by your provider 
- Additional medications for managing high blood pressure, sugar, and/or cholesterol levels 
- Lifestyle changes  
o Healthy eating 
o Exercise 
o Quitting smoking 
 
Adapted from Endocrinology & Diabetes Unit and Child & Adolescent Psychiatry Department,  
Department of Learning & Development, & Vancouver Coastal Health. (n.d.).  Atypical antipsychotics & 
metabolic monitoring.  Accessed from http://www.bcchildrens.ca/health-professionals/clinical-
resources/endocrinology-diabetes/atypical-antipsychotics 
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APPENDIX K: STAFF ROLES AND RESPONSIBILITIES 
 
Children and Adolescents Diagnosed with a Bipolar Spectrum Disorder  
Taking an Atypical Antipsychotic 
 
Staff Member Task Task Description 
Office assistant 
Printing and compiling 
toolkit 
Toolkits will need to be printed and put into a folder 
for providers to keep in their office 
Provider 
Using toolkit with 
appropriate patients 
Toolkits should be used in patients ages 5-18 who are 
diagnosed with a bipolar spectrum disorder and who 
are taking an atypical antipsychotic 
Provider 
Placing toolkit contents on 
the chart or giving 
information to 
patient/caregiver 
Documentation forms should be filed in the chart and 
educational handouts should be given to the patient 
and/or caregiver 
Office assistant 
or  
Provider 
Measuring/documenting 
vital signs 
Blood pressure, pulse, height, weight, BMI, and waist 
circumference (if applicable) should be completed and 
staff completing should sign his/her name 
Provider Reviewing vital signs 
Sign vital sign documentation form, include vital signs 
in the progress note, and/or document on the provider 
documentation form 
Provider Ordering lab work 
Complete and sign lab form and document the 
intervention in the progress note and/or on the 
intervention documentation form 
Office assistant  
Placing a copy of the lab 
order on the chart 
File a copy of the completed lab for to show 
documentation that lab work was ordered 
Provider 
Following up with patient 
regarding completion of 
lab work 
Ask during appointment if lab work was completed 
Office assistant Filing lab results in chart 
File results on the chart correctly and flag them for 
review, document this on the communication tool  
Provider Reviewing lab results 
Sign and date lab results, include lab values in the 
progress note, and/or document on the provider 
documentation form 
Provider 
Ordering referral to 
PCP/specialist 
Complete and sign referral form 
Office assistant 
Having patient complete 
release of information 
form 
Have patient/caregiver sign release of information 
form for the PCP/specialist of the referral 
Office assistant 
Faxing referral form and 
attachments 
Fax referral forms, lab results, and other pertinent 
notes to PCP/specialist, document this on the 
communication tool 
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APPENDIX L: AUDIT TOOL 
 
Practice Guideline for Metabolic Monitoring Audit Tool 
 
Directions: Calculate the amount of time the patient has been on an atypical antipsychotic 
medication (AAP) by using the first documented use of an AAP.  Mark on the chart below where 
the patient falls.  Anything falling under that column should be documented in order to satisfy 
the outcome measure.  Only the items that are due at the time of the visit should be audited.  
 
Examples are listed below. 
 
 Monitoring Protocol for Patients on AAPs* 
Months Since 
Initiation 
       
Example 1: 3 months     X    
Example 2: 8 months     X   
 
Baseline  
(0-3weeks) 
4 
Weeks 
8 Weeks 
12 
Weeks 
Quarterly 
(4-11 
months) 
Annually 
Every 5  
Years 
Personal/Family 
History 
X     X  
Weight (BMI) X X X X X   
Waist Circumference X     X  
Blood Pressure X   X  X  
Fasting Plasma 
Glucose 
X   X  X  
Fasting Lipid Profile X   X   X 
 
Example 1: At the time of the patient’s last visit, it had been 3 months since the patient was 
started on an AAP.  Height and weight (BMI), blood pressure, a fasting plasma glucose, and a 
fasting lipid profile are due and should be documented in the chart.  
 
Example 2:  At the time of the patient’s last visit, it had been 8 months since the patient was 
started on an AAP.  Height and weight (BMI) should be documented  
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Patient Name: ___________________________________  DOB:__________________ 
 
1st Atypical Antipsychotic Start Date: ________________  Date: __________________ 
 
 Monitoring Protocol for Patients on AAPs* 
Months Since 
Initiation 
       
 
Baseline  
(0-3weeks) 
4 Weeks 8 Weeks 12 Weeks 
Quarterly 
(4-11 months) 
Annually 
Every 
5  
Years 
Personal/Family 
History 
X     X  
Weight (BMI) X X X X X   
Waist 
Circumference 
X     X  
Blood Pressure X   X  X  
Fasting Plasma 
Glucose 
X   X  X  
Fasting Lipid 
Profile 
X   X   X 
 
 
Phase I Outcome Measures Audit Checklist 
 
Outcome Measure 
  / 
X 
Measure Components Required 
Acceptable Evidence that Measure was Satisfied 
Toolkit employed for patient aged 
5-18 with bipolar spectrum disorder 
taking an atypical antipsychotic 
 Forms of toolkit present on chart 
 
Color sticker on outside of chart 
Personal and family history 
assessment completed by the 
provider  
 
Completed assessment form at baseline and annually 
Metabolic labs ordered at 
recommended intervals 
 
Fasting Plasma Glucose ordered at baseline, 12 weeks, and annually 
Copy of lab form on chart  OR 
Order documented in assessment 
note 
 
Fasting lipid profile ordered at baseline, 12 weeks, and every 5 years 
Copy of lab form on chart  OR 
Order documented in assessment 
note 
Vital signs taken and documented 
on chart 
 Height/Weight (BMI) taken at baseline, 4 weeks, 8 weeks, 12 weeks, 
and quarterly thereafter 
Measurement documented on vital sign documentation form 
 Blood pressure taken at baseline, 12 weeks, and annually 
Measurement documented on vital sign documentation form 
 Waist circumference measured at baseline and annually 
Measurement documented on vital sign documentation form 
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APPENDIX M: COMMUNICATION DOCUMENTATION FORM 
 
Date Message/Action Taken Staff Signature 
Provider 
Signature 
1/2/34 Lab results filed on chart and flagged for 
Dr. C to review 
D. Smith, Office 
Asnt 
 
2/3/45 
 
Faxed lab results and referral form to 
patient’s PCP 
D. Smith, Office 
Asnt 
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APPENDIX N: ATYPICAL ANTIPSYCHOTIC TREATMENT CHECKLIST AND 
INTERVENTION DOCUMENTATION FORM 
 
 
Patient Name: ____________________________________ DOB: _________________ 
 
 
Psychiatric Diagnosis(es): ________________________________________________________ 
 
Medical Diagnosis(es): __________________________________________________________ 
 
Atypical Antipsychotic Medication/Dose: ____________________________________________ 
 
 
 
Intervention Date  Notes Date  Notes 
Pretreatment     
Discuss metabolic risks     
Discuss diet     
Discuss physical activity     
Risk/benefit assessment     
Discuss smoking cessation     
Lab work ordered     
During Treatment     
Discuss metabolic risks     
Discuss diet     
Discuss physical activity     
Risk/benefit assessment     
Discuss smoking cessation     
Lab work ordered     
Refer to dietician     
Refer to specialist     
Refer to PCP     
Consult with another provider     
Lab work forwarded to 
PCP/other provider 
    
Discuss signs/symptoms of 
diabetes/DKA 
    
Switch antipsychotic medication     
Change medication dose     
Addition of medication to 
counter metabolic side effects 
    
Other: 
 
    
Other: 
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APPENDIX O: PROJECT IMPLEMENTATION TIMELINE 
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APPENDIX P: MEASUREMENT GUIDE FOR VITAL SIGNS 
 
 
Children and Adolescents Diagnosed with a Bipolar Spectrum Disorder  
Taking an Atypical Antipsychotic 
 
 
Measurement Technique 
Height 
- Shoes off 
- Patient standing with heels, back, and shoulders in contact with the stadiometer 
- Feet together 
- Gently straighten 
- Hold head aligned with lower portion of eye orbit in line with the middle 
portion of the ear 
Weight - Anything heavy off (shoes, jacket, etc.) 
BMI 
Calculation 
- Divide weight in pounds by height in inches 
- Divide that number by the height in inches again 
- Multiple that number by 703 
- [W (lbs) / (H (in) x H (in))] x 703 
Waist 
Circumference 
- Use a flexible tape of adequate length 
- Have the patient stand erect with abdomen relaxed, feet shoulder-width apart, 
weight evenly distributed, arms loosely by their side 
- Make the measurement horizontally at the line of the umbilicus/belly button 
- Ask the patient to breathe normally 
- Alternately – ask the patient to hold one end of the tape over their belly button 
and spin around to decrease amount of physical touch 
Blood Pressure 
- Choose the right cuff size for the patient’s arm: the dotted line on the cuff 
should rest between the solid lines 
- Have the patient sit down and relax 
- Heavy clothing should be removed or the sleeve rolled up 
- The Artery  sign should be placed on the inside of the arm 
- Do not talk to the patient while measuring and ask that they wait until it is 
finished to talk 
 
 
 
Adapted from:  Provincial Mental Health Metabolic Program (2010).  Measurement guide for 
metabolic assessment, screening, & monitoring tool.  Accessed from 
http://www.bcchildrens.ca/health-professionals/clinical-resources/endocrinology-
diabetes/atypical-antipsychotics.  
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APPENDIX Q: SUMMARY TABLES OF CHART AUDIT DATA 
 
 
Table 1: Summary of Chart Audit Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Chart Audit Data with Provider Data 
 
P1 – provider 1; P2 – provider 2, P3, provider 3 
 
 
 
 
 
 
 
 
 
 
Week 0 
% 
Week 2 
% 
Week 4 
% 
Week 6 
% 
Date of Audit  10/22/17 11/5/17 11/19/17 
Dates Audited  10/9-10/20 10/23-11/3 11/6-11/17 
Outcome Measure     
Fasting Plasma Glucose 8.3 13.3 28.6 33.3 
Fasting Lipid Panel 8.3 13.3 28.6 33.3 
Height/Weight 27.1 53.3 85.7 100 
Vital Signs 89.6 100 100 100 
Waist Circumference 0 6.7 71.4 88.9 
Metabolic Assessment 0 26.7 28.6 33.3 
Sticker on Chart 0 20 42.9 33.3 
Forms on Chart 0 26.7 42.9 33.3 
Number of Charts Reviewed 48 15 7 9 
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APPENDIX R: PHASE II AND PHASE III OUTCOME MEASURES 
 
Phase II: 
5. Metabolic laboratory study results were properly filed for review by office staff 
a. Evidenced by the presence of the laboratory results in the chart 
b. Evidenced by the documentation of receipt of and filing of results by office staff 
on communication tool in the chart (Appendix M) 
6. Metabolic laboratory study results were reviewed by the provider 
a. Evidenced by provider signature on laboratory results 
b. Evidenced by the documentation of results in visit note or on lab documentation 
form (Appendix E) 
7. Vital signs (specifically blood pressure, height, weight, BMI, and waist circumference) 
were reviewed by the provider at chronological increments suggested by the guidelines 
a. Evidenced by documentation of each of the vital signs on the visit note or 
acknowledgement of the values on the documentation sheet with provider 
signature  
Phase III: 
8. Abnormal metabolic laboratory study and/or vital sign results resulted in an action by the 
provider 
a. Evidenced by the documentation in the visit note or on the intervention form 
(Appendix N) of one or more of the following: 
i. Medication change 
ii. Medication dosage change 
iii. Referral to PCP or specialist 
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iv. Evidenced by copy of completed referral form in chart (Appendix I), 
documentation of referral completion by office staff, or documented 
communication between provider and PCP or specialist 
v. Patient/caregiver education on interventions to improve values 
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